aTyr Pharma (LIFE) Tops Q2 EPS by 6c

aTyr Pharma (NASDAQ: LIFE) reported Q2 EPS of ($0.65), $0.06 better than the analyst estimate of ($0.71).

Financial Guidance

As of June 30, 2016, we had $96.6 million in cash, cash equivalents and investments and 23.7 million shares of common stock outstanding.

We currently expect that our cash, cash equivalents and investments will be sufficient to fund our anticipated operations into 2018.

For earnings history and earnings-related data on aTyr Pharma (LIFE) click here.

You May Also Be Interested In

• WD-40 Co. (WDFC) Tops Q3 EPS by 76c; offers guidance
• ImmuCell reports 11.5% sales rise in Q2 2026, 20.9% gain for first half
• JPMorgan Downgrades PhysicsWallah Ltd (PWL:IN) to Neutral